The antiprotozoal drug, pentamidine, has been reported to induce hypoglycaemia associated with inappropriately high plasma insulin concentrations, followed by insulindependent diabetes mellitus. It has been suggested that this drug can be toxic to the islet B cell, inducing early cytolytic release of insulin leading to B cell destruction. In order to test this hypothesis, mouse and rat islets were incubated with pentamidine at concentration range of 5 x 10 -11 to 5 x 10 -3 mol/1 and exposure times of 3-48 h. The B cell responses to glucose + theophylline and to arginine were suppressed by pentamidine, while insulin release in non-stimulatory conditions was increased. These effects were dose-dependent, time-dependent and irreversible. They were significant for 5 x 10 -7 mol/1 pentamidine, which is a concentration relevant to therapeutic uses. These effects developed more slowly than the toxic effects of streptozotocin and alloxan at the same molar concentration in vitro. 51Chromium release and Trypan blue exclusion tests support the hypothesis that pentamidine produces islet cell necrosis.
B cell, diabetogenic drugs.
The antiprotozoal drug, pentamidine, is an aromatic diamidine used for the chemotherapy of trypanosomiasis, leishmaniasis and Pneumocystis Carinii pneumonitis [1, 2] . Hypoglycaemic attacks have occurred in 91 cases [3] [4] [5] . Inappropriately high plasma insulin concentrations have been documented in some of these patients [3] . Diabetes mellitus has also been observed in 31 reported cases [6] . In eight of these subjects, diabetes developed after the occurrence of hypoglycaemia and was usually insulin-dependent. For these reasons we have suggested that pentamidine is toxic to B cells, inducing early cytolytic release of insulin, B cell destruction, insulinopenia and diabetes [3] . In order to check this hypothesis, mouse and rat islets were exposed to pentamidine in vitro, and basal and stimulated insulin release was measured.
Material and Methods

Mouse and Rat Islet Preparations
Adult DBA/2 mice and Wistar rats (CNRS, Orleans, France) fed ad libitum were used. Islets were prepared as described by Lacy and Kostianovsky [7] , pancreatic tissue from five mice or one rat pancreas being treated with 15mg collagenase (150mU/mg; Boehringer, Mannheim, FRG). After manual shaking, islets were picked up under a dissecting microscope (Nikon, SMZ2, Tokyo, Japan) and transferred to Petri dishes set on ice. Islets were then either put on incubation plates or perifused directly.
Incubation Experiments
Five islets were suspended in each well of Falcon microtest plates (Becton-Dicldnson, Rockville, Maryland, USA) in MEM Eagle medium (Flow Laboratories, Rockville, Maryland) supplemented with 10% fetal calf serum, glutamine (2mmol/1), sodium pyruvate (lmmol/1), non-essential amino-acids (0.814mg/1), streptomycin (100 ktg/ml), penicillin (100 mU/l). This medium, containing glucose (5.5 mmol/1), was equilibrated with 02 and CO2 (95%-5%) and the final pH was 7.4. The medium was called basal medium.
Pentamidine dimethane sulphonate (Specia, Paris, France) was dissolved in basal medium. Freshly isolated islets were incubated in basal medium (5 islets/250 ~tl) for 24 h at 37 ~ with 02 and CO2 (95% and 5%), in the presence of pentamidine 5 x 10 -11 to 5 x 10 -3 mol/1. Islets were also exposed to pentamidine 5 x 10 -3 and 5 x 10 -5 mol/1 for 3-48 h.
At the end of the incubation period, islets were washed twice and then exposed to the basal or stimulatory media (250 l.d/well) for 30 rain. The standard stimulatory medium consisted of the basal medium, except for the addition of glucose (16.5 mmol/l) + theophylline (5 mmol/1). In other experiments, the basal medium was supplemented with arginine (20 mmol/1). Similar experiments were performed with sodium methane sulphonate (5 x 10 -5 mol/1) in place of pentamidine dimethane sulphonate. To test the reversibility of pentamidine effects, islets were also exposed to pentamidine 5 x l0-Smol/1 for 24 h, washed three times and re-incubated for 24 h in a pentamidinefree medium, before the stimulation described above. 
Direct Perifusion Experiments
Freshly isolated islets were placed in a flow-through perifusion system [8, 9] . Three perifusion media were prepared. The basal medium, derived from Krebs-Ringer physiological solution, contained the following components: NaC1 (120 retool/l), KCI (4.7 mmol/l), MgSO4 (0.8 mmol/l), CaCI2 (2.5 mmol/l), KHzPO4 (1.2retool/I), NaHCO3 (25 mmol/1), human serum albumin (0.60%; Centre National de Transfusion Sanguine, Paris, France), aprotinin (2.000 lx/ml; Choay, Paris, France), glucose (5 mmol/1), sodium pyruvate, fumarate and glutamate (5 retool/1 each; Sigma, St. Louis, Missouri, USA). The final pH was adjusted to 7.4 by adding 4-6 drops of normal sodium hydroxide. The stimulatory medium was essentially similar, except for glucose concentration which was 20 retool/1 and the addition of theophylline (5 mmol/1). The pentamidine-containing medium was similar to the basal medium, except for the addition of pentamidine (10-* mol/1). Final pH was adjusted to 7.4 after complete dissolution of the drug. All three media were warmed to 37 ~ and gassed with a mixture of 02 + COz (95% + 5%) before and during perifusion experiments, the pH and temperature being repeatedly monitored. Chambers were perifused at a constant flow rate of 1 ml/min. Experiments lasted for a maximum of 160 rain. Samples were collected at predetermined intervals of time, cooled on ice and frozen at -20 ~ until assayed. Viability of islets was tested at the end of all experiments by the Trypan blue exclusion test.
Incubation 4-Perifusion Experiments
Freshly isolated islets were incubated for 18 h in supplemented MEM Eagle medium in the presence or in the absence of pentamidine (10 .-4 tool/l), then transferred to the perifusion chambers, perifused in basal medium for 40rain and stimulated by glucose (20mmol/ 1) + theophylline.
Trypan Blue Exclusion Test
Islets were exposed to a 0.5% Trypan blue isotonic solution for 1 min, then examined under a dissecting microscope (Nikon SMZ 2, Tokyo, Japan) under a white episcopic light, using x 40 magnification.
51Chromium Cytotoxicity Assay
Dispersed islet cells were prepared as described previously (10) and their viability was tested by the Trypan blue exclusion test; only suspensions with at least 90% viable cells were retained. Cells were incubated at 37 ~ for 1-5 h with 80 mCi of Na25~Cr 04 (CNTS, Paris, France), washed twice and then incubated for 24 h in the presence of pentamidine at a concentration range of 5.10 -11 to 5.10 -3 tool/1. The supematants were counted in a gamma scintillation spectrometer (Packard, Chicago, Illinois). The 51Cr release was compared with that of cells lysed with distilled water.
Assessment of Hormone Damage
During incubations, the insulin may have been partly damaged. This damage might have been reduced either by pentamidine, which is chemically close to the antiprotease molecule benzamidine [11] , or augmented by thelysosomal enzymes of necrotic islet cells.
To assess the extent of insulin damage, 125I-insulin (500 p.Ci/~xg -CNTS, Paris, France) was incubated with islets and pentamidine for 2 and 48 h. Supematants were then treated by dextran-coated charcoal [12] . It was assumed that the damaged hormone (i. e. free iodine and small peptides) corresponded to the fraction which was not retained by the dextran-coated charcoal.
Determination and Expression of Results
Insulin (IRI) was determined by radioimmunoassay [13] using charcoal for the separation of free and bound hormone, purified rat insulin as a standard and porcine ~2sI-insulin as a tracer. It was verified that pentamidine (10 -3 mol/1) did not interfere with the assay. Results are expressed as mean + SEM. Statistical significance of differences was analysed by using the Student's t-test for non-paired values.
Results
Influence of Pentamidine on the B Cell Responses to Stimuli
Incubation Experiments: Dose-Dependency: As shown in Figure 1 , mouse islets, incubated for 24h in the basal control medium, responded to the stimulation by glucose (20 mmol/l) + theophylline (5 mmol/1) by a significant IRI release (0.53 _+ 0.03 versus 0.03 + 0.01 mU/ 30 min per five islets in basal medium, n = 6; p < 0.001). Pentamidine (5 x 10 -9 and 5 x 10 -11 mol/1) did not modify significantly this B cell response. But this response was significantly lower than control in islets treated by pentamidine 5x10-7moI/1. This response was abolished for concentrations of 5 x 10 -5 and 5 x 10 -3 mol/1.
Time-Dependency: this was analysed for pentamidine concentrations of 5 • 10 -5 and 5 x 10 -3 mol/1 (Fig.2) . While a significant B cell response to stimulus was observed in all control experiments (Fig. 2, upper panel) , no response occurred in the case of islets exposed to pentamidine 5 x 10 -5 mol/1 and 5 x 10 -3 mol/1, from the shortest (i. e. 3 h) to the longest (48 h) time of exposure (Fig. 2, central and lower panels) . The B cell response from the pentamidine-treated islets was in all cases significantly lower than that from control islets in the same stimulatory medium. Thus suppression of IRI release was proportionate to the duration of exposure to the drug. When islets had been pre-incubated for 24 h with pentamidine (5 x 10 -5 mol/1), and then washed and allowed to stay for a further 24 h in a pentamidine-free medium, there was still no B cell response to glucose + theophylline (Fig. 3) .
When islets were treated with sodium methane sulphonate ( 
Incubation 4-perifusion:
Islets were incubated for 18 h in supplemented MEM Eagle medium as described above in the presence or the absence of pentamidine (10-4mol/1), then transferred to the perifusion system and stimulated by arginine (20 mmol/1)+theophylline (5 mmol/1). The B cell response in pentamidine-treated rat islets was dramatically lower than in control islets (Fig.4, upper panel) . In contrast, somatostatin release was similar to that in control islets (Fig. 4, lower panel) . Similar results were obtained as regards the B cell response to glucose (20mmol/1) + theophylline (5 mmol/1) from mouse or rat islets similarly treated by pentamidine then perifused in vitro (data not shown).
Direct perifusion experiments:
Freshly isolated rat islets were perifused immediately, exposed to pentamidine (10-4mol/1) for 40min, then stimulated by glucose (20 mmol/1)+theophylline (5 mmol/1). The mean IRI release following pentamidine exposure was 73 +11 versus 55 _+ 8 lxU/min per 40 islets in control perifusions (n =10; NS), but for the stimulatory period the mean increase in IRI secretion was lower in the pentamidinetreated islets than in the control islets (0.04_+ 0.01 versus 0.08 _+ 0.01 mU/min per 40 islets; p < 0.05). The switch from basal to pentamidine medium induced no massive IRI release during a 120 rain observation period.
Influence of Pentamidine on Non-stimulated IRI Release
Incubation experiments: As already noted in Figures 1  and 2 , pentamidine exerted complex influences on nonstimulated IRI release. In a dose-response study, pentamidine (5 x 10 -9 and 5 • 10 -11 mol/1) did not alter the basal IRI release in mouse islets at the end of the 24 hincubation period (Table1). At concentrations of 5 • 10 -7 to 5 • 10 -3 mol/1, IRI release was dramatically increased. Islets were also serially incubated for 3-48 h to analyse the influence of the duration of the incubation period ( Table 2 ). The IRI concentration in basal medium did not vary significantly. In the presence of the drug, the IRI level was markedly increased for the three shortest exposure times.
Modifications in hormone damage might have contributed to these complex effects of pentamidine.
125I-labelled insulin was incubated with basal medium plus islets in the absence and in the presence of pentamidine (5 x 10 -3 mol/1) and aprotinin (20,000 U/ ml). Incubations were conducted at 37 ~ for 2-48 h. Aliquots of supernatants were then added to 500 gl dex- Results expressed as mean + SEM of six experiments in each group Islets were maintained in a non-stimulatory medium (glucose 5.5 mmol/1) in the presence of pentamidine. Then insulin was assayed in supernatant in absence of any further stimulation, a p < 0.001 statistically significant difference between pentamidine-treated islets and the corresponding control group tran-coated charcoal in the presence of 50 ~L1 normal sheep serum. The percentage radioactivity not retained by dextran-coated charcoal was increased in the supernatants after 48 h in the presence of pentamidine-treated islets: 57% versus 13% in case of control islets or tracer alone. This damage was slightly reduced (52% instead of 57%) by the addition of aprotinin. This suggests that the increase in basal IRI concentration observed after pentamidine exposure was not due to a reduction of hormone damage. On the contrary, the damage of tracer was increased, presumably due to cell necrosis and release of intracellular proteases. Similar results were obtained when 125I-glucagon was incubated with islets and pentamidine.
Characterization of B Cell Necrosis 51Chromium release test:
The chromium release from dispersed islet cells incubated for 24 h in basal medium with pentamidine (5 x 10 -7 to 5 X 10 -3 mol/1) was significantly higher than control values (Fig. 5) . This increase was dose-dependent.
Trypan blue exclusion test: Dark blue islets were, in all instances, easily distinguishable from the bright white islets. The percentage of blue islets was < 1% in the case of control islets either freshly isolated or incubated for 18 h in MEM Eagle medium. It was also < 1% when islets were exposed to pentamidine (10-4mol/1) for 120 min or less. This percentage increased progressively and reached 55% of islets after 5 h. It was 95-100% after a 18-h long exposure to the drug at a concentration of l0 -4 mol/1. This time-course differed greatly from those obtained after exposure to streptozotocin or alloxan, the toxic effects of which were much faster than those of pentamidine at the same concentrations.
Discussion
Our data suggest that pentamidine exerts two distinct influences on the B cells: (1) an impairment of B cell response to glucose and arginine detectable as early as 1 h after exposure to the drug, and (2) a cytolytic process strongly suggested by 5tChromium release, the Trypan blue test and excessive release of insulin in non-stimulatory conditions. This leakage may be similar to that observed when alloxan and streptozotocin are used [14, 15] , albeit less acute in the case of pentamidine than with alloxan [15] . Streptozotocin, added to dispersed islet cells incubated in vitro, induces a pattern very similar to that obtained with pentamidine, i. e. IRI release in non-stimulatory conditions and no response to glucose + theophylline (data not shown).
The clinical relevance of our experiments is substantiated by: (1) the time-course of published clinical events, where early hypoglycaemic attacks precede the onset of diabetes mellitus [3] and (2) the concentrations of pentamidine measured in plasma and tissues of treat-R Sa'i et al.: Pentamidine, A New Diabetogenic Drug ed patients (i. e. 10 -6 mol/1) which correspond to those toxic for islets in vitro [16, 18] . Furthermore, in several patients with pentamidine-induced diabetes, renal insufficiency was present [3] . As pentamidine is partly excreted by the kidney, this condition may favour the accumulation of the drug in the tissues. In some cases, successive treatment courses have an additive effect on the impairment of glucose tolerance [3, 20] . Although slight variations in glucose tolerance have been described in pentamidine-treated rabbits [21] , no animal model of pentamidine-induced diabetes mellitus is currently available in vivo in laboratory rodents.
Two pentamidine salts are currently used in therapeutics: isethionate and mesylate (or dimethane sulphonate). The latter may be the more diabetogenic [6, 19, 20] . Since isethionate can alter hormone release by itself [22] , it is important to note that: (1) pentamidine dimethane sulphonate was used in the present study, and (2) sodium methane sulphonate had no effect. Further work is needed to clarify the mechanism of action of the drug on islet B cells at the molecular level. It has been shown in protozoa and bacteria that pentamidine interferes mainly with protein synthesis and ribosomal activities [23] [24] [25] [26] , with mitochondrial structure and oxidative metabolism [26] [27] [28] [29] . It also impairs several enzymatic systems, including that of kallikrein [30] , which may be involved in the insulin secretory process [31] .
Islet B cells were specifically affected by pentamidine in the concentration range studied here, while D cell function was not impaired. Further work, currently in progress, suggests that rat hepatocytes and some non-pancreatic cukured cell lines are less sensitive to the pentamidine toxicity than islet B cells. If confinned, this would provide a new tool for the analysis of B cell metabolism and further potential for the medical treatment of insulinomas.
